ASD - ETF AI Analysis
Top Page
Defiance Autism Impact ETF (ASD)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Leading Holdings
Several of the largest positions, including BrightSpring Health Services and MapLight Therapeutics, have shown strong gains so far this year, helping support the fund’s results.
Focused Health Care Exposure
With most of the portfolio in health care companies, the ETF is tightly aligned with its autism impact theme and benefits when this segment of the market does well.
Global Diversification
Holdings spread across the U.S., Europe, Asia, and Australia help reduce the risk of being tied to the economic conditions of just one country.
Negative Factors
High Expense Ratio
The fund’s relatively high fee means more of any returns are eaten up by costs compared with cheaper ETFs.
Small Asset Base
With a low level of assets under management, the ETF may face higher trading spreads and a greater risk of closure than larger, more established funds.
Sector Concentration Risk
Heavy weighting in health care stocks means the fund could be hit hard if this sector faces regulatory changes or market pressure.
ASD vs. SPDR S&P 500 ETF (SPY)
AUM1.25M
RegionNorth America
Expense Ratio0.79%
BetaN/A
IssuerDefiance
Inception DateJun 01, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedVettaFi Autism Impact Index - USD - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume781
30 Day Avg. Volume736
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.21Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering35
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASD Summary
The Defiance Autism Impact ETF (ASD) is a health care–focused fund that follows the VettaFi Autism Impact Index. It invests in companies that support people on the autism spectrum and the broader neurodiverse community through treatments, diagnostics, education, and assistive technologies. Well-known names in the fund include Eli Lilly and Teva. Investors might consider ASD if they want growth potential in health care while also supporting autism-related impact and charities. However, because it is concentrated in one sector and a specific theme, its price can go up and down more than a broadly diversified stock fund.
How much will it cost me?This ETF has an expense ratio of 0.79%, which means you’ll pay about $7.90 per year for every $1,000 you invest. That’s higher than the average ETF because it’s a specialized, impact-focused fund that tracks a niche autism-related index rather than a broad, low-cost market index.
What would affect this ETF?ASD could benefit if demand grows for autism-related health services, telehealth, and innovative treatments, especially as U.S. healthcare spending and support for neurodiversity and impact investing continue to rise, helping many of its specialized holdings. On the other hand, it could be hurt by changes in healthcare regulations or reimbursement, setbacks in drug development for companies like Eli Lilly, Jazz Pharmaceuticals, or Teva, or a broad downturn in the U.S. health care sector that would weigh on its concentrated portfolio.
ASD Top 10 Holdings
ASD leans heavily into health care, with U.S.-listed names doing most of the heavy lifting and a few overseas players adding flavor. BrightSpring and Lifestance are two of the fund’s main engines right now, both rising on solid growth stories tied to behavioral and clinical care. Eli Lilly adds blue-chip heft, steadily contributing thanks to its strong drug pipeline. On the flip side, Repligen’s rebound has been choppy and Neuren is clearly losing steam, which has been a drag. Overall, the fund is thematically focused but not dominated by any single giant.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| BrightSpring Health Services, Inc. | 4.49% | $56.01K | $12.58B | 200.42% | 67 Neutral | |
| MapLight Therapeutics, Inc. | 3.97% | $49.49K | $1.19B | ― | ― | |
| Lifestance Health Group | 3.69% | $45.94K | $3.33B | 71.03% | 61 Neutral | |
| Jazz Pharmaceuticals | 3.44% | $42.89K | $14.49B | 111.94% | 64 Neutral | |
| Revvity | 3.21% | $40.02K | $11.22B | 7.50% | 67 Neutral | |
| Pearson | 3.18% | $39.59K | £6.82B | 7.65% | 73 Outperform | |
| Repligen | 3.15% | $39.26K | $7.38B | 8.82% | 68 Neutral | |
| Teva | 3.11% | $38.80K | ₪115.88B | 60.08% | 61 Neutral | |
| Eli Lilly & Co | 3.08% | $38.40K | $1.06T | 41.86% | 72 Outperform | |
| Neuren Pharmaceuticals Limited | 2.95% | $36.71K | AU$1.64B | -3.74% | 78 Outperform |
ASD Technical Analysis
Negative
―
Price Trends
Market Momentum
10.84
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ASD, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of 10.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASD.
ASD Peer Comparison
Comparison Results
Performance Comparison
ASD
Defiance Autism Impact ETF
24.82
0.20
0.81%
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
PBJ
Invesco Dynamic Food & Beverage ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents